PDS Biotechnology Corp Q4 FY2024 earnings call

• Initiated VERSATILE-003 Phase 3 clinical trial for Versamune HPV + pembrolizumab in first line recurrent and/or metastatic HPV16-positive head and neck squamous cell carcinoma.
• FDA cleared IND application for Versamune MUC1 and PDS01ADC combination for metastatic colorectal cancer, with collaboration with the National Cancer Institute.
• Data from IMMUNOCERV Phase 2 study on Versamune HPV with chemoradiation for locally advanced cervical cancer presented at ASTRO.
• Rationale and trial design for NCI-led study on PDS01ADC + enzalutamide for recurrent prostate cancer discussed at Cytokines 2024.
• 2024 net loss was approximately $37.6 million, down from $42.9 million in 2023; R&D expenses decreased by $5.2 million, G&A expenses decreased by $1.5 million, but net interest expense increased.

No specific product segment financial performance with revenue contributions reported as the transcript does not detail such breakdowns.

• Progressing VERSATILE-003 Phase 3 trial with initial site initiation and participation from Phase 2 trial sites.
• Plan to raise capital stepwise to fund trials, considering equity and non-dilutive sources.
• VERSATILE-003 Phase 3 trial has interim data readouts planned, with potential for accelerated FDA review based on durable responses and improved clinical outcomes.

• Forward-looking statements subject to risks and uncertainties including clinical trial outcomes, regulatory approvals, and funding challenges as outlined in SEC filings.

Q: What is the enrollment trajectory and site balance for VERSATILE-003?

A: First site initiated this month, with almost all Phase 2 trial sites re-engaged, speeding up enrollment. Familiarity with the drug and belief in results from Phase 2 help.

Q: How do you view the current funding environment for current studies?

A: Recently raised $11 million, funding environment is difficult, but plan to raise capital stepwise using equity and non-dilutive sources.

Q: Rationale for VERSATILE-003 trial size reduction and interim readouts?

A: Durable responses and improved clinical outcomes allowed trial design adjustment. Interim readouts planned for early FDA discussions regarding potential accelerated approval.

Q: Timing of MUC1 candidate and TARP program?

A: MUC1 trial led by NCI, timeline not specified yet. TARP program timeline not provided, focus on VERSATILE-003 trial.